📊 ESMC Key Takeaways
Is Escalon Medical Corp. (ESMC) a Good Investment?
Escalon Medical is a distressed company with deteriorating fundamentals, burning cash at an unsustainable rate while generating minimal revenue growth. Negative operating cash flow of -432.4K, combined with persistent operating losses and a weak equity base of only 1.8M, indicates the company is in financial distress with limited runway.
Escalon Medical shows some earnings improvement, but the core fundamentals remain weak: revenue growth is minimal, operating margins are still negative, and the business is consuming cash. The balance sheet is lightly levered and liquidity is adequate, but persistent negative operating cash flow and thin profitability leave little margin for error in a small-scale business.
Why Buy Escalon Medical Corp. Stock? ESMC Key Strengths
- Low leverage with debt-to-equity of only 0.01x provides some financial flexibility
- Current ratio of 1.65x indicates adequate short-term liquidity to cover immediate obligations
- Established presence in electromedical apparatus sector with existing revenue base of 6.3M
- Very low leverage with debt/equity of 0.01x and minimal long-term debt
- Adequate near-term liquidity with a 1.65x current ratio and 1.06x quick ratio
- Net loss narrowed materially year over year, indicating some improvement in cost control or operating stability
ESMC Stock Risks: Escalon Medical Corp. Investment Risks
- Negative free cash flow of -436.8K annually indicates unsustainable cash burn with only 337.4K cash available
- Operating losses of -104.0K and net losses of -142.2K show inability to generate profitability at current scale
- Minimal revenue growth of 0.5% YoY combined with negative operating margins suggests business model deterioration or lack of market demand
- Cash runway appears critically limited; at current burn rate, available cash depleted within months
- No insider buying activity in last 90 days, suggesting lack of management confidence
- Revenue growth of just 0.5% suggests weak business momentum and limited operating leverage
- Negative operating cash flow and free cash flow indicate the business is not self-funding
- Negative margins, ROE, and ROA show the company is still not generating acceptable returns on its asset and equity base
Key Metrics to Watch
- Operating cash flow - must return to positive territory
- Revenue growth rate - currently stagnant; needs 10%+ growth to stabilize
- Cash balance and runway - monitor for financing needs or dilution events
- Path to operating profitability - critical for survival
- Operating cash flow and free cash flow trend
- Operating margin improvement alongside sustained revenue growth
Escalon Medical Corp. (ESMC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Escalon Medical Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ESMC Profit Margin, ROE & Profitability Analysis
ESMC vs Healthcare Sector: How Escalon Medical Corp. Compares
How Escalon Medical Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Escalon Medical Corp. Stock Overvalued? ESMC Valuation Analysis 2026
Based on fundamental analysis, Escalon Medical Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Escalon Medical Corp. Balance Sheet: ESMC Debt, Cash & Liquidity
ESMC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Escalon Medical Corp.'s revenue has grown significantly by 15% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
ESMC Revenue Growth, EPS Growth & YoY Performance
ESMC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$21.2K | $-0.02 |
| Q2 2025 | $2.9M | -$21.2K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Escalon Medical Corp. Dividends, Buybacks & Capital Allocation
ESMC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Escalon Medical Corp. (CIK: 0000862668)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ESMC
What is the AI rating for ESMC?
Escalon Medical Corp. (ESMC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ESMC's key strengths?
Claude: Low leverage with debt-to-equity of only 0.01x provides some financial flexibility. Current ratio of 1.65x indicates adequate short-term liquidity to cover immediate obligations. ChatGPT: Very low leverage with debt/equity of 0.01x and minimal long-term debt. Adequate near-term liquidity with a 1.65x current ratio and 1.06x quick ratio.
What are the risks of investing in ESMC?
Claude: Negative free cash flow of -436.8K annually indicates unsustainable cash burn with only 337.4K cash available. Operating losses of -104.0K and net losses of -142.2K show inability to generate profitability at current scale. ChatGPT: Revenue growth of just 0.5% suggests weak business momentum and limited operating leverage. Negative operating cash flow and free cash flow indicate the business is not self-funding.
What is ESMC's revenue and growth?
Escalon Medical Corp. reported revenue of $6.3M.
Does ESMC pay dividends?
Escalon Medical Corp. does not currently pay dividends.
Where can I find ESMC SEC filings?
Official SEC filings for Escalon Medical Corp. (CIK: 0000862668) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ESMC's EPS?
Escalon Medical Corp. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ESMC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Escalon Medical Corp. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ESMC stock overvalued or undervalued?
Valuation metrics for ESMC: ROE of -8.0% (sector avg: 15%), net margin of -2.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ESMC stock in 2026?
Our dual AI analysis gives Escalon Medical Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ESMC's free cash flow?
Escalon Medical Corp.'s operating cash flow is $-432.4K, with capital expenditures of $4.4K. FCF margin is -7.0%.
How does ESMC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.3% (avg: 12%), ROE -8.0% (avg: 15%), current ratio 1.65 (avg: 2).